dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.date.accessioned | 2014-05-27T11:29:28Z | |
dc.date.accessioned | 2022-10-05T18:50:09Z | |
dc.date.available | 2014-05-27T11:29:28Z | |
dc.date.available | 2022-10-05T18:50:09Z | |
dc.date.created | 2014-05-27T11:29:28Z | |
dc.date.issued | 2013-05-07 | |
dc.identifier | Medicina (Brazil), v. 46, n. 1, p. 47-55, 2013. | |
dc.identifier | 0076-6046 | |
dc.identifier | 2176-7262 | |
dc.identifier | http://hdl.handle.net/11449/75368 | |
dc.identifier | 2-s2.0-84876964265 | |
dc.identifier | 9740488644443034 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3924305 | |
dc.description.abstract | Study Model: Retrospective study. Study Objective: To characterize statin treatment management due to lipid alterations and side effects throughout statin treatment in basic healthcare unit. Methods: Medical reports of women from a basic healthcare unit were analyzed, obtaining: disease presence, regular medication prescription, statin type and dosage, biochemical exams results, musculoskeletal complaints, and statin use cessation, going back the information until the medical consultation of first prescription. Results: Prescribed statins were Simvastatin and Atorvastatin at low doses (10-20 mg). Dose (48,4%) and/or type (25,4%) alterations occurred for lipid profile adequacy. Lipid levels were reduced without creatine kinase elevation. Treatment withdrawn (30,6%) was mainly due to their own decision (74%), which was strongly associated with records of musculoskeletal complaints (Odds Ratio: 6,40[1,53-26,78]). Conclusion: Statin treatment was effective in reducing serum lipid levels and self-reported pain was underestimated, characterizing the major limiting factor for treatment adherence. | |
dc.language | por | |
dc.relation | Medicina (Brazil) | |
dc.relation | 0,125 | |
dc.relation | 0,125 | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | Dyslipidemias | |
dc.subject | HMG-CoA | |
dc.subject | Medication therapy management | |
dc.subject | Public health | |
dc.subject | Statins | |
dc.subject | atorvastatin | |
dc.subject | creatine kinase | |
dc.subject | lipid | |
dc.subject | simvastatin | |
dc.subject | consultation | |
dc.subject | creatine kinase blood level | |
dc.subject | disease association | |
dc.subject | disorders of lipid and lipoprotein metabolism | |
dc.subject | drug withdrawal | |
dc.subject | female | |
dc.subject | health care facility | |
dc.subject | human | |
dc.subject | lipid analysis | |
dc.subject | lipid blood level | |
dc.subject | low drug dose | |
dc.subject | medical information | |
dc.subject | musculoskeletal disease | |
dc.subject | prescription | |
dc.subject | retrospective study | |
dc.title | Caracterização do tratamento medicamentoso com estatinas em unidade básica de saúde | |
dc.type | Artigo | |